| Nov 12 |
Earnings Scheduled For November 12, 2024
|
| Nov 11 |
Lexicon Pharmaceuticals Q3 2024 Earnings Preview
|
| Nov 6 |
Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference
|
| Nov 6 |
A diabetes drug, twice rejected, stumbles again — but its developer persists
|
| Nov 5 |
Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease
|
| Nov 5 |
Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024
|
| Nov 4 |
Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss
|
| Nov 1 |
Sector Update: Health Care Stocks Rise Late Afternoon
|
| Nov 1 |
Top Midday Decliners
|
| Nov 1 |
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
|
